Literature DB >> 25202697

Are hematopoietic stem cells involved in hepatocarcinogenesis?

Antonio Facciorusso1, Matteo Antonino1, Valentina Del Prete1, Viviana Neve1, Maria Principia Scavo1, Michele Barone1.   

Abstract

THE LIVER HAS THREE CELL LINEAGES ABLE TO PROLIFERATE AFTER A HEPATIC INJURY: the mature hepatocyte, the ductular "bipolar" progenitor cell termed "oval cell" and the putative periductular stem cell. Hepatocytes can only produce other hepatocytes whereas ductular progenitor cells are considerate bipolar since they can give rise to biliary cells or hepatocytes. Periductular stem cells are rare in the liver, have a very long proliferation potential and may be multipotent, being this aspect still under investigation. They originate in the bone marrow since their progeny express genetic markers of donor hematopoietic cells after bone marrow transplantation. Since the liver is the hematopoietic organ of the fetus, it is possible that hematopoietic stem cells may reside in the liver of the adult. This assumption is proved by the finding that oval cells express hematopoietic markers like CD34, CD45, CD 109, Thy-1, c-kit, and others, which are also expressed by bone marrow-derived hematopoietic stem cells (BMSCs). Few and discordant studies have evaluated the role of BMSC in hepatocarcinogenesis so far and further studies in vitro and in vivo are warranted in order to definitively clarify such an issue.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); carcinogenesis; hematopoietic; stem cells

Year:  2014        PMID: 25202697      PMCID: PMC4141297          DOI: 10.3978/j.issn.2304-3881.2014.06.02

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  67 in total

1.  Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells.

Authors:  Ignazia Prigione; Federica Benvenuto; Paola Bocca; Luca Battistini; Antonio Uccelli; Vito Pistoia
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

Review 2.  Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment.

Authors:  Michael P Lisanti; Ubaldo E Martinez-Outschoorn; Barbara Chiavarina; Stephanos Pavlides; Diana Whitaker-Menezes; Aristotelis Tsirigos; Agnieszka Witkiewicz; Zhao Lin; Renee Balliet; Anthony Howell; Federica Sotgia
Journal:  Cancer Biol Ther       Date:  2010-09-19       Impact factor: 4.742

3.  Bone marrow progenitors are not the source of expanding oval cells in injured liver.

Authors:  Anuradha Menthena; Niloyjyoti Deb; Michael Oertel; Petar N Grozdanov; Jaswinder Sandhu; Shalin Shah; Chandan Guha; David A Shafritz; Mariana D Dabeva
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

4.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells.

Authors:  Stephanie Ma; Kwok-Wah Chan; Liang Hu; Terence Kin-Wah Lee; Jana Yim-Hung Wo; Irene Oi-Lin Ng; Bo-Jian Zheng; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2007-04-15       Impact factor: 22.682

5.  Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.

Authors:  Miki Murata; Koichi Matsuzaki; Katsunori Yoshida; Go Sekimoto; Yoshiya Tahashi; Shigeo Mori; Yoshiko Uemura; Noriko Sakaida; Junichi Fujisawa; Toshihito Seki; Kazuki Kobayashi; Koutaro Yokote; Kazuhiko Koike; Kazuichi Okazaki
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

6.  Bone marrow-derived cells fuse with hepatic oval cells but are not involved in hepatic tumorigenesis in the choline-deficient ethionine-supplemented diet rat model.

Authors:  Koji Kubota; Junpei Soeda; Ryousuke Misawa; Motohiro Mihara; Shiro Miwa; Hirohiko Ise; Masafumi Takahashi; Shinichi Miyagawa
Journal:  Carcinogenesis       Date:  2008-01-03       Impact factor: 4.944

7.  Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats.

Authors:  Anna C Piscaglia; Thomas D Shupe; Seh-Hoon Oh; Antonio Gasbarrini; Bryon E Petersen
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

8.  RalB signaling: a bridge between inflammation and cancer.

Authors:  Alberto Mantovani; Frances Balkwill
Journal:  Cell       Date:  2006-10-06       Impact factor: 41.582

9.  Stem cells and their niche in homeostasis/regeneration and disease.

Authors:  Yukiko M Yamashita; Tudorita Tumbar
Journal:  Mol Biol Cell       Date:  2014-03       Impact factor: 4.138

10.  The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines.

Authors:  Sabrieh Amini; Fardin Fathi; Jafar Mobalegi; Heshmatollah Sofimajidpour; Tayyeb Ghadimi
Journal:  Anat Cell Biol       Date:  2014-03-13
View more
  12 in total

1.  Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials.

Authors:  Antonio Facciorusso; Francesco Bellanti; Rosanna Villani; Veronica Salvatore; Nicola Muscatiello; Fabio Piscaglia; Gianluigi Vendemiale; Gaetano Serviddio
Journal:  United European Gastroenterol J       Date:  2016-10-03       Impact factor: 4.623

2.  Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis.

Authors:  Antonio Facciorusso; Gaetano Serviddio; Nicola Muscatiello
Journal:  World J Hepatol       Date:  2016-06-28

3.  Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases.

Authors:  Antonio Facciorusso; Valentina Del Prete; Nicola Crucinio; Gaetano Serviddio; Gianluigi Vendemiale; Nicola Muscatiello
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

Review 4.  Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients.

Authors:  Antonio Facciorusso; Raffaele Licinio; Nicola Muscatiello; Alfredo Di Leo; Michele Barone
Journal:  World J Hepatol       Date:  2015-08-08

Review 5.  Granulocyte colony-stimulating factor-producing hepatocellular carcinoma with abrupt changes.

Authors:  Hiroaki Nagata; Shuhei Komatsu; Wataru Takaki; Tokunari Okayama; Yasunori Sawabe; Michiaki Ishii; Mitsuo Kishimoto; Eigo Otsuji; Hiroshi Konosu
Journal:  World J Clin Oncol       Date:  2016-10-10

6.  Cellular Origins of Regenerating Nodules and Malignancy in the FAH Model of Liver Injury after Bone Marrow Cell Transplantation.

Authors:  Pei-Rong Wang; Yi Li
Journal:  Stem Cells Int       Date:  2015-12-29       Impact factor: 5.443

7.  Prognostic value of p53 mutation for poor outcome of Asian primary liver cancer patients: evidence from a cohort study and meta-analysis of 988 patients.

Authors:  Xiajie Wen; Fengmin Lu; Shuang Liu
Journal:  Onco Targets Ther       Date:  2016-12-08       Impact factor: 4.147

8.  Biological effects of bone marrow mesenchymal stem cells on hepatitis B virus in vitro.

Authors:  Wei-Ping Zheng; Bo-Ya Zhang; Zhong-Yang Shen; Ming-Li Yin; Yi Cao; Hong-Li Song
Journal:  Mol Med Rep       Date:  2017-03-15       Impact factor: 2.952

9.  Adipose-Derived Mesenchymal Stem Cell Exosomes Suppress Hepatocellular Carcinoma Growth in a Rat Model: Apparent Diffusion Coefficient, Natural Killer T-Cell Responses, and Histopathological Features.

Authors:  Sheung-Fat Ko; Hon-Kan Yip; Yen-Yi Zhen; Chen-Chang Lee; Chia-Chang Lee; Chung-Cheng Huang; Shu-Hang Ng; Jui-Wei Lin
Journal:  Stem Cells Int       Date:  2015-08-02       Impact factor: 5.443

10.  Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.

Authors:  Chuan Shen; Chenghong Peng; Baiyong Shen; Zhecheng Zhu; Ning Xu; Tao Li; Junjie Xie
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.